Live feed07:00:00·1021dPRReleasevia QuantisnowCymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary CholangitisByQuantisnow·Wall Street's wire, on your screen.CBAY· CymaBay Therapeutics Inc.Health Care
